Natural products as a rich source of tau-targeting drugs for Alzheimers disease

Future Medicinal Chemistry

Volumn 4, Issue 13, 2012, Pages 1751-1761

  Calcul, Laurent ^a   Zhang, Bo ^b   Jinwal, Umesh K ^a   Dickey, Chad A ^b   Baker, Bill J ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIXA; ACETYLCHOLINE; ALZHAMED; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; CINNAMALDEHYDE DERIVATIVE; CINNAMON EXTRACT; CURCUMIN; DONEPEZIL; FLURBIPROFEN; GALANTAMINE; GELDANAMYCIN; GOSSYPETIN; HOMOTAURINE; ISOFLAVAN DERIVATIVE; LIGNAN DERIVATIVE; MEMANTINE; MEMOX; METHYLENE BLUE; MINOCYCLINE; MYRICANOL; MYRICETIN; MYRICETIN 3 RHAMNOSIDE; NATURAL PRODUCT; PACLITAXEL; PROCYANIDIN DERIVATIVE; REMBER; RIVASTIGMINE; TACRINE; TANSHINONE IIA; TARENFLURBIL; TAU PROTEIN; TIDEGLUSIB; TURMERIC; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; REVIEW; STREPTOMYCES; STRUCTURE ACTIVITY RELATION; TAXUS BREVIFOLIA; UNITED STATES;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL AGENTS; DRUG DISCOVERY; HUMANS; TAU PROTEINS;

EID: 84865749287     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.124     Document Type: Review

References (91)

1. Prince M, Bryce R, Ferri C. World Alzheimer Report. Alzheimer's Disease International, London, UK, 1-36 (2011).
2. Freeman WJ. Alzheimer: the life of a physician and the career of a disease. J. Am. Med. Assoc. 293, 745-746 (2005).
3. Lott IT, Head E. Alzheimer disease and down syndrome: factors in pathogenesis. Neurobiol. Aging 26, 383-389 (2005).
4. Waring SC, Rosenberg RN. Genome-wide association studies in Alzheimer disease. Arch. Neurol. 65, 329-334 (2008).
5. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology including Alzheimer's disease. Proc. Natl Acad. Sci. USA 103, 5644-5651 (2006).
6. Bartus RT, Dean RL, Pontecorvo MJ, Flicker C. The cholinergic hypothesis: a historical overview, current perspective, and future directions. Ann. NY Acad. Sci. 444, 332-358 (1985).
7. Garcia ML, Cleveland DW. Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. Curr. Opin. Cell Biol. 13, 41-48 (2001).
8. Cassimeris L, Spittle C. Regulation of microtubule associated protein. Int. Rev. Cytol. 210, 163-226 (2001).
9. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathywith presenile dementia. Proc. Natl Acad. Sci. USA 95, 7737-7741 (1998).
10. Hutton M, Lendon CL, Rizzu, P et al. Association of missense and5́-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705 (1998).
11. Hardy J, Orr H. The genetics of neurodegenerative diseases. J. Neurochem. 97, 1690-1699 (2006).
12. Goedert M, Spillantini MG, Crowther RA et al. Tau gene mutation in familial progressive subcortical gliosis. Nat. Med. 5, 454-457 (1999).
13. Van Marum RJ. Current and future therapy in Alzheimer's disease. Fundam. Clin. Pharmacol. 22, 265-274 (2008).
14. Santacruz K, Lewis J, Spires T et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-448 (2005).
15. Spires-Jones TL, de Calignon A, Matsui T et al. In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons. Neuroscience 28, 862-867(2008).
16. Congdon EE, Necula M, Blackstone RD, Kuret J. Potency of a tau fibrillization inhibitor is influenced by its aggregation state. Arch. Biochem. Biophys. 465, 127-135 (2007).
17. Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, La Ferla FM. Reduction of soluble Ab and tau, but not Soluble Ab alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 281, 39413-39423 (2006).
18. Goedert M. Tau gene mutations and their effects. Mov. Disord. 20, 45-52 (2005).
19. Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochim. Biophys. Acta Mol. Basis Dis. 1739, 240-250 (2005).
20. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. Selective inhibition of Alzheimer disease-like tau aggregationby phenothiazines. Proc. Natl Acad. Sci. USA 93, 11213-11218 (1996).
21. Dickey CA, Kamal A, Lundgren K et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest. 117, 648-658 (2007).
22. Green RC, Schneider LS, Amato DA et al. Effect of Tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease. J. Am. Med. Assoc. 302, 2557-2564 (2009).
23. Gauthier S, Aisen PS, Ferris SH et al. Effect of Tramiprosate in Patients with Mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J. Nutr. Health Aging 13, 550-557 (2009).
24. Lyketsos CG, Breitner JC, Green RC et al. Naproxen and celecoxib do notprevent AD in early results from a randomized controlled trial. Neurology 68, 1800-1808 (2007).
25. Crystal H, Dickson D, Fuld P et al. Clinicopathological studies in dementia: nondemented subjects with pathological confirmed Alzheimer's disease. Neurology 38, 1682-1687 (1988).
26. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Ber.) 82, 239-259 (1991).
27. Kramp VP. List of drugs in development for neurodegenerative diseases: update October 2011. Neurodegen. Dis. 9, 210-283 (2012).
28. Mount C, Downton C. Alzheimer disease: progress or profit? Nat. Med. 12, 780-784 (2006).
29. Areosa SA, Sherriff F, McShane R. Menantine for dementia. Coch. Data. Syst. Rev. 2, 1-77 (2006).
30. Brekov S, Georgieva L, Kondakova V et al. Plant sources of Galathamine: phytochemical and biotechnological aspects. Biotechnol. Biotechnol. Eq. 23, 1170-1176 (2009).
31. Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer disease: a comparison of tolerability and pharmacology. Drug Saf. 19, 465-480 (1998).
32. Al-Rashid ZF, Hsung RP. (+)-arisugacin A - computational evidence of a dual binding site covalent inhibitor of acetylcholinesterase. Bioorg. Med. Chem. Lett. 21, 2687-2691 (2011).
33. Polydoro M, Acker CM, Duff K, Castillo PE, Davies PJ. Age-dependent impairment of cognitive and synaptic function in the tau mouse model of tau pathology. Neurosci. 29, 10741-10749 (2009).
34. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod.75, 311-335 (2012).
35. Necula M, Chirita CN, Kuret J. Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases. Biochemistry 44, 10227-10237 (2005).
36. de Calignon A, Fox LM, Pitstick R et al. Caspase activation precedes and leads to tangles. Nature 464, 1201-1204 (2010).
37. Eisenberg D, Nelson R, Sawaya MR et al. The structural biology of protein aggregation diseases: fundamental questions and some answers. Acc. Chem. Res. 39, 568-575 (2006).
38. Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15, 112-119 (2009).
39. Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat. Rev. Drug Discov. 6, 464-479 (2007).
40. Gong CX, Iqbal K. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr. Med. Chem. 15, 2321-2328 (2008).
41. Medina M, Castro A. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr. Opin. Drug Discov. Dev. 11, 533-543 (2008).
42. Selenica ML, Jensen HS, Larsen AK et al. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the post natal rat model of tau hyperphosphorylation. Br. J. Pharmacol. 152, 959-979 (2007).
43. Ishihara T, Hong M, Zhang B et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron. 24, 751-762 (1999).
44. Zhang B, Maiti A, Shively S et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl Acad. Sci. USA 102, 227-223 (2005).
45. Williams P, Sorribas A, Howes MJR. Natural products as a source of Alzheimer's drug leads. Nat. Prod. Rep. 28, 48-77 (2011).
46. Da Rocha MD, Dias Viegas FP, Campos HC et al. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer's disease. CNS Neurol. Disord. Drug Targets 10, 251-270 (2011).
47. Gu Y, Nieves JW, Stern Y, Luchsinger JA, Scarmeas N. Food combination and Alzheimer disease risk: a protective diet. Arch. Neurol. 67, 699-706 (2010).
48. Howes MJ, Houghton PJ. Ethnobotanical treatment strategies against Alzheimer's disease. Curr. Alzheimer Res. 9, 67-85 (2012).
49. Shytle RD, Bickford PC, Rezai-zadeh K et al. Optimized turmeric extracts have potent anti-amyloidogenic effects. Curr. Alzheimer Res. 6, 564-571 (2009).
50. Shytle RD, Tan J, Bickford PC et al. Optimized turmeric extract reduces b-amyloid and phosphorylated tau protein burden in Alzheimer's transgenic mice. Curr. Alzheimer Res. 9, 500-506 (2012).
51. Jones J, Lebar MD, Jinwal UK et al. The diarylheptanoid (+)-aR,11S-myricanol and two flavones from bayberry (Myricacerifera) destabilize the microtubule-associated protein tau. J. Nat. Prod. 74, 38-44 (2011).
52. Mounnissamy VM, Kavimani S, Gunasegaran R. Antibacterial activity of gossypetin isolated from hibiscus sabdariffa. Antiseptic 99, 81-82 (2009).
53. Shiota S, Shimizu M, Mizushima T. Marked reduction in the minimum inhibitory concentration (MIC) of beta-lactams in methicillin-resistant Staphylococcus aureus produced by epicatechingallate, an ingredient of green tea (Camellia sinensis). Biol. Pharm. Bull. 22, 1388-1390 (1999).
54. Taniguchi S, Suzuki N, Masuda M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280, 7614-7623 (2005).
55. Peterson DW, George RC, Scaramozzino F, Lapointe NE, Anderson RA, Graves DJ et al. Cinnamon extract inhibits tau aggregation assiocated with Alzheimer's disease in vitro. J. Alzheimers Dis. 17, 585-597 (2009).
56. Pasinetti GM, Ksiezak-Reding H, Santa- Maria I, Wang J, Ho L. Development of a grape seed polyphenolic extract with antioligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies. J. Neurochem. 114, 1557-1568 (2010).
57. Luvone T, De Filippis D, Esposito G, D'Amico A, Izzo AA. The spice sage and its active ingredient rosmarinicacid protect PC12 cells from amyloid-b peptide-induced neurotoxicity. J. Pharmacol. Exp. Ther. 317, 1143-1149 (2006).
58. Shi LL, Yang WN, Chen XL et al. The protective effects of tanshinone IIA on neurotoxicity induced by b-amyloid protein through calpain and the p35/Cdk5 pathway in primary cortical neurons. Neurochem. Int. 61(2), 227-235 (2012).
59. Ohtsuki K, Miyai S, Yamaguchi A, Morikawa K, Okano T. Biochemical characterization of novel lignansisolated from the wood of Taxus yunnanensis as effective stimulators for glycogen synthase kinase-3b and the phosphorylation of basic brain proteins by the kinase in vitro. Biol. Pharm. Bull. 35, 385-393 (2012).
60. Li W, Sperry JB, Crowe A et al. Inhibition of tau fibrillation by oleocanthal via the reaction of the amino group of tau. J. Neurochem. 110, 1339-1351 (2009).
61. Pickhardt M, Gazova Z, von Bergen M et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J. Biol. Chem. 280, 3628-3635 (2005).
62. Radenahmad N, Saleh S, Sawangjaroen K et al. Young coconut juice, a potential therapeutic agent that could significantly reduce some pathologies associated with Alzheimer's disease: novel findings. Br. J. Nutr. 105, 738-746 (2011).
63. Li L, Liu J, Yan X et al. Protective effects of ginsenoside Rd against okadaic acid-induced neurotoxicity in vivo and in vitro. J. Ethnopharmacol. 138, 135-141 (2011).
64. Chaudan NB. Effect of aged garlic extract on APP processing and tau phosphorylationin Alzheimer's transgenic model Tg2576. J. Ethnopharm. 108, 385-394 (2006).
65. Miethbauer S, Gaube F, Möllmann U et al. Antimicrobial, antiproliferative, cytotoxic, and tau inhibitory activity of rubellins and caeruleoramularin produced by the phytopathogenic fungusrcollo-cygni. Planta Med. 75, 1523-1525 (2009).
66. Bedin M, Gaben AM, Saucier C, Mester J. Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest. Int. J. Cancer 109, 643-652 (2004).
67. Forloni G, Colombo L, Girola, Tagliavini F, Salmona M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 487, 404-407 (2007).
68. Choi Y, Kim H, Shin KY et al. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology 32, 2393-2404 (2007).
69. FamilianA, Boshuizen RS, Eikelenboom P, Veerhuis R. Inhibitory effect of minocycline on amyloid beta fibril formation and human microglial activation. Glia 53, 233-240 (2006).
70. Noble W, Garwood C, Stephenson J, Kinsey AM, Hanger DP, Anderton BH. Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB J. 23, 739-750 (2009).
71. Zhang B, Carroll J, Trojanowski JQ et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J. Neurosci. 32, 3601-3611(2012).
72. Cornejo A, Jimenez JM, Caballero L, Melo F, Maccioni RB. Fulvic acid inhibits of tau fibrils associated with Alzheimer's disease. J. Alzheimer Dis. 27, 143-153 (2011).
73. Carrasco-Gallardo C, Guzman L, Maccioni RB. Shilajit: a natural phytocomplex with potential precognitive activity. Int. J. Alzheimer Dis. 1-4 (2012).
74. Das V, Miller JH. Microtubule stabilization by peloruside A and paclitaxel rescues degenerating neurons from okadaic acid-induced tau phosphorylation. Eur. J. Neurosci. 35, 1705-1717 (2012).
75. Alfano G, Cimino G, De Stefano S. Palinurin, a new linear sesterterpene from a marine sponge. Experientia 35, 1136-1137 (1979).
76. Sakai R, Higa T, Jefford CW, Bernardinelli G. Manzamine A, a novel antitumor alkaloid from a sponge. J. Am. Chem. Soc. 108, 6404-6405 (1986).
77. CiminoG, de Rosa S, de Stefano S, Mazzarella L, Puliti R, Sodano G. Isolation and x-ray crystal structure of a novel bromo-compound from two marine sponges. Tetra. Lett. 23, 767-768 (1982).
78. Hamann M. Alonso A, Martin-Aparicio E et al. Glycogen synthasekinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of themanzamine alkaloids. Potential for Alzheimer's disease. J. Nat. Prod. 70, 1397-1405 (2007).
79. Meijer L, Thunnissen A, White AW et al. Inhibition of cyclin-dependent kinases, GSK-3b and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 7, 51-63 (2000).
80. Meijer L, Skaltsounis AL, Magiatis P et al. GSK-3-selective inhibitors derived from tyrianpurple indirubins. Chem. Biol. 10, 1255-1266 (2003).
81. Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink AL. The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J. Biol. Chem. 279, 26846-26857 (2004).
82. Kocisko DA, Baron GS, Rubenstein R, Chen J, Kuizon S, Caughey B. Drugs and natural products protein formation in a library of 2,000 new inhibitors of scrapie-associated prion. J. Virol. 77, 10288-10294 (2003).
83. Monti MC, Margarucci L, Tosco A, Riccio R, Casapullo A. New insights on the interaction mechanism between tau protein and oleocanthal, an extra-virgin olive-oil bioactive component. Food Funct. 2, 423-428 (2011).
84. Alam MI, Beg S, Samad A et al. Strategy for effective brain drug delivery. Eur. J. Pharm. Sci. 40, 385-403 (2010).
85. Yang F, Lim GP, Begum AN. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892-5901 (2005).
86. Janle EM, Lila MA, Wood L et al. Kinetics and tissue distribution on 14C-labeled grape polyphenol fractions. FASEB J. 21, 837 (2007).
87. Jager AK, Saaby L. Flavonoids and the CNS. Molecules 16, 1471-1485(2011).
88. Jin J, Lee WS, Joo KM et al. Preparation of blood-brain barrier-permeable paclitaxel-carrier conjugate and its chemotherapeutic activity in the mouse glioblastoma model. Med. Chem. Commun. 2, 270-273 (2011).
89. Dickey C, Lebar MD, Baker BJ, Jones J: WO2012012798 (2012).
90. Gordillo DA, Diaz ID, Gil AM et al.: WO054221 (2004).
91. ClinicalTrials.gov. http://clinicaltrials.gov